DEVELOPMENT OF QSP PLATFORM MODEL FOR PREDICTING ALTERNATE PRIMING DOSE
A comprehensive multi-scale in silico approach for predicting antibody-drug conjugate clinical efficacy across oncological indications
A quantitative systems pharmacology (QSP) model for predicting the efficacy
CLINICAL DOSE PREDICTION FOR CHIMERIC ANTIGEN RECEPTOR
Development of Immuno-Oncology (IO) QSP Platform
QSP Model of Rheumatoid Arthritis
Development of mPBPK-target engagement model
A Bootstrapping Method to Optimize
Supporting dose decisions for Antibody Drug Conjugates
Does Progressive Disease Justify Pembrolizumab discontinuation
